Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Amneal shares leap on better-than-feared guidance

Published 03/01/2024, 08:52 AM
© Reuters.
AMRX
-

BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) today announced financial results for the fourth quarter ended December 31, 2023, showcasing an EPS beat and a slight revenue miss compared to analyst expectations. The company reported an adjusted EPS of $0.14, surpassing the analyst estimate of $0.09. However, revenue for the quarter was $617 million, falling short of the consensus estimate of $634.89 million.

The company's full-year 2024 financial guidance indicated an optimistic outlook, with projected EPS ranging from $0.53 to $0.63, closely bracketing the analyst consensus of $0.59. Revenue forecasts for the same period are set between $2.55 billion and $2.65 billion, with the midpoint slightly below the consensus estimate of $2.58 billion.

Amneal's stock responded positively to the news, climbing 8.5% as investors reacted to the better-than-feared guidance. This upsurge reflects confidence in the company's future performance despite the mixed fourth-quarter results.

For the fourth quarter of 2023, Amneal saw a 1% increase in net revenue YoY, from $610 million in the fourth quarter of 2022 to $617 million. The growth was primarily driven by a 38% increase in AvKARE revenues due to new product launches and a 2% rise in Specialty revenues, led by key branded products. However, these gains were partially offset by a 9% decline in Generics revenues.

The company reported a net loss of $99 million for the quarter, a significant increase from the $4 million net loss in the same period last year. This was largely due to non-cash intangible asset impairment charges and costs related to term loan refinancing. Adjusted EBITDA for the quarter was $142 million, down 8% YoY, attributed to investments in research and development and commercial activities to drive future growth.

Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal, commented on the company's performance, stating, "Amneal had a very successful year in 2023 as we delivered strong execution and growth across our diversified pharmaceutical business. We are starting 2024 with substantial momentum and key catalysts, including complex high-value products, biosimilars, and specialty, to further expand our reach."

The company's full-year 2023 net revenue increased by 8% to $2.39 billion compared to the previous year, with growth across all business segments. The net loss for the year improved to $84 million from $130 million in 2022. Adjusted EBITDA for the full year was $558 million, a $44 million increase from the previous year, reflecting strong revenue growth and continued operating expense leverage.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.